Aim-To assess parathyroid hormone related protein (PTHrP) as a candidate biochemical marker of invasion of the mandible by oral squamous cell carcinoma. Methods-Tumour PTHrP concentrations were quantitated by immunoassay, and PTHrP was detected by immunohistochemistry, in a cohort of 24 primary squamous cell carcinomas of the mandible. Results-PTHrP was identified in all tumours examined, but no correlation was found between scores of the intensity and) or consistency of staining or tumour PTHrP concentrations and the histological classification of tumour invasion. Conclusion-Although PTHrP was present in all squamous tumours studied, there was no correlation between PTHrP expression and pattern of tumour invasion. However, tumour derived PTHrP may act locally to influence tumour growth and differentiation and resorption of bone. (J7 Clin Pathol 1995;48:300-303) Keywords: Squamous cell carcinomas, parathyroid hormone related protein.
In normal adult bone there is a continuous but slow process of remodelling involving osteoclastic resorption and osteoblastic new bone formation. These processes mainly involve the endosteal bone surfaces with much more limited change occurring on the periosteal aspect. The invasion of bone by tumour may be associated with an increase in both osteoclastic and osteoblastic activity. Before Tissue was extracted by homogenisation in 10 volumes of 1 M acetic acid as previously described. 7 After one hour of incubation on ice, the homogenate was centrifuged at 13 000 x g for five minutes and the supernatant fluid was frozen, lyophilised and reconstituted in assay diluent for quantitation of PTHrP by immunoassay.
PTHrP 1-86 immunoreactivity in lyophilised tumour extracts (1 ml) and column fractions (0 53 ml) reconstituted in assay buffer, phosphate buffered saline ((PBS), pH 7-4, containing 0-25% Polypep, 0-1% Triton x 100 and 0-01% sodium azide) was measured by a validated two-site immunoradiometric assay (IRMA).'6 The assay is specific for residues 17-61 of PTHrP and the detection limit of the assay is 0-23 pmol/l. Tissue extracts were diluted serially for assay (for example, 1 in 5 to 1 in 160). The protein content of reconstituted tumour extracts was determined by a protein microassay (BioRad).
Gel filtration chromatography was performed as previously described.'8 Tissue extract, reconstituted in 1 ml assay diluent, was applied to a Bio-Gel P100 column (100 x 1 cm) equilibrated in 1 M acetic acid. Fractions of 0-53 ml were collected, lypohilised and reconstituted in assay diluent for quantitation of PTHrP 1-86 activity. The column was calibrated with the following protein standards and iodinated PTHrP peptides: bovine serum albumin, 66 kDa; carbonic anhydrase, 29 kDa; "5I-PTHrP 1-141, 16 kDa; cytochrome c, 12.4 kDa; '251-PTHrP 1-86, 9-9 kDa; aprotinin, 6-5 kDa; and '25I-(Tyr')-PTHrP-34, 4*1 kDa. tions treated with non-immune serum or preabsorbed PTHrP antibody were negative. Immunohistochemical staining did not correlate with the pattem of invasion. There were no significant correlations between the intensity and/or consistency of staining for PTHrP and the invasiveness or degree of differentiation of the tumour (table 1) .
Tumour concentrations ofPTHrP are shown in table 2. In all cases PTHrP was extracted from tumours diluted in parallel to the standard in the immunoassay. PTHrP 1-86 activity was detected in all eight tumours examined, although no concordance was found between the concentrations measured and the intensity or consistency of staining by immunohistochemistry. Tumour PTHrP concentrations were in the range 48-3898 fmol/gtissue (median 1683 fmol/g tissue) and 13-5361 pmol/g protein (median 459 pmol/g protein) ( 28 In conclusion, although PTHrP peptide was present in all oral squamous cell carcinomas studied, the intensity and/or consistency of staining was unrelated to the pattern of tumour invasion. However, it is possible that tumour derived PTHrP may act locally to influence growth and dedifferentiation and resorption of bone.
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